CAS 1126623-89-9 Axitinib-[d3] - Isotope / BOC Sciences

General Information
Catalog: BLP-011798
CAS: 1126623-89-9
Molecular Formula: C22H15D3N4OS
Molecular Weight: 389.49

General Information

Catalog: BLP-011798

CAS: 1126623-89-9

Molecular Formula: C22H15D3N4OS

Molecular Weight: 389.49

Chemical Structure

Description	Axitinib-[d3] is the labelled analogue of Axitinib. Axitinib is a tyrosine kinase inhibitor that blocks the activation of VEGFR1, VEGFR2, VEGFR3, c-kit, and PDGFRβ (IC50 = 1.2, 0.25, 0.29, 1.7, and 1.6 nM, respectively). It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models.
Synonyms	Axitinib D3; N-(Methyl-d3)-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]benzamide; AG 013736-d3; Axitinib-d3 (N-methyl-d3)
IUPAC Name	2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]-N-(trideuteriomethyl)benzamide
Related CAS	319460-85-0 (unlabelled)
Canonical SMILES	CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4
InChI	InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+/i1D3
InChI Key	RITAVMQDGBJQJZ-VOTVRPQJSA-N
Purity	95% by HPLC; 98% atom D
Solubility	Soluble in DMSO (Slightly), Methanol (Slightly)
Appearance	White to Off-white Solid
Storage	Store at -20°C

Axitinib-[d3] is a deuterated form of Axitinib, a potent VEGFR inhibitor used primarily in cancer research and treatment. Here are some key applications of Axitinib-[d3]:

Pharmacokinetic Studies: Axitinib-[d3] is often utilized in pharmacokinetic studies to track and analyze the behavior of Axitinib in the body. The deuterium atoms provide a distinct mass that aids in differentiating the drug from its metabolites during mass spectrometry analysis. This information helps in understanding the absorption, distribution, metabolism, and excretion of the drug.

Drug Metabolism Research: Axitinib-[d3] is crucial in studying the metabolic pathways of Axitinib. By comparing the metabolism of the deuterated and non-deuterated forms, researchers can determine the specific enzymes involved and the rates of metabolic transformations. This can help in identifying potential metabolic bottlenecks and optimizing drug formulations.

Drug Interaction Studies: In preclinical research, Axitinib-[d3] is used to explore potential drug-drug interactions involving Axitinib. The deuterium label allows scientists to precisely monitor changes in Axitinib’s pharmacokinetics when co-administered with other compounds. This information is vital for predicting adverse interactions and ensuring the safety of combination therapies.

Quantitative Analysis in Clinical Trials: During clinical trials, Axitinib-[d3] can be employed as an internal standard for the accurate quantification of Axitinib levels in biological samples. This provides enhanced precision in measuring drug concentrations and ensures the reliability of pharmacokinetic and pharmacodynamic data. Reliable measurements are essential for accurate dose determination and therapeutic monitoring.